InMode Ends Sale Talks: No Good Offers Found
InMode has stopped its review of buyout or merger proposals after deciding none were good enough for shareholders.
Already have an account? Sign in.
InMode has stopped its review of buyout or merger proposals after deciding none were good enough for shareholders.
Congress approves sweeping housing legislation to accelerate construction and limit Wall Street investors. Trump delays signing, but markets cheer the supply-boosting reforms.
Her first major trades since early 2026.
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.